Janus Henderson Group
RIGL icon

Janus Henderson Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Janus Henderson Group’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.67M Buy
135,877
+99,659
+275% +$3.35M ﹤0.01% 1058
2025
Q4 		$1.55M Sell
36,218
-194,504
-84% -$7.33M ﹤0.01% 1464
2025
Q3 		$6.54M Buy
+230,722
New +$6.9M ﹤0.01% 849
2022
Q4 		– Sell
-6,867
Closed -$80K – 2494
2022
Q3 		$80K Buy
6,867
+3,440
+100% +$46.5K ﹤0.01% 2502
2022
Q2 		$39K Sell
3,427
-6
-0.2% -$121 ﹤0.01% 2566
2022
Q1 		$102K Hold
3,433
– – ﹤0.01% 2558
2021
Q4 		$91K Buy
3,433
+1,727
+101% +$52.1K ﹤0.01% 2512
2021
Q3 		$62K Buy
+1,706
New +$67.2K ﹤0.01% 2169

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group's RIGL Position: Q1 2026 in Review

Janus Henderson Group increased its Rigel Pharmaceuticals (RIGL) stake by 275% in Q1 2026, buying an estimated $3.35M and bringing the position to 135,877 shares worth $3.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1058.

Janus Henderson Group first reported a position in RIGL in Q3 2021 and has held it in 8 quarters since. The position peaked at $6.54M in Q3 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Janus Henderson Group held 135,877 shares of Rigel Pharmaceuticals worth $3.67M as of Q1 2026.
  • Janus Henderson Group bought 99,659 Rigel Pharmaceuticals shares in Q1 2026, an estimated $3.35M.
  • Rigel Pharmaceuticals made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1058 holding.
  • Janus Henderson Group first reported a position in Rigel Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
  • Janus Henderson Group's Rigel Pharmaceuticals position peaked at $6.54M in Q3 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.